LONDON–(BUSINESS WIRE)–Global law firm Goodwin announced today that Malcolm Bates, David
Mardle, Tim Worden and Adrian Rainey will join its Life
Sciences and Technology
Companies practices in the firm’s London
office. Mardle joined the firm yesterday, while Bates, Worden and Rainey
will join following the completion of their notice periods.
-
Malcolm Bates is among the leading life science licensing and
collaboration lawyers in the UK and Europe. He advises on
transactions, including licenses, collaborations and distribution,
manufacturing, outsourcing and R&D projects, as well as regulatory
matters and contract and patent disputes. -
David Mardle is a highly experienced corporate lawyer, having
advised on private and public financings and M&A transactions in the
life sciences and technology sectors for nearly 20 years. -
Tim Worden focuses on licensing and collaboration transactions,
R&D and clinical trial agreements, and regulatory matters. His
expertise also includes the IP and regulatory aspects of M&A
transactions and public and private financings. -
Adrian Rainey is one of the leading corporate lawyers in the UK
and Europe specializing in representing technology companies and
venture capital firms. He advises on private financings and M&A
transactions across the software, internet, financial technology and
digital media industries, as well as in the life sciences and medical
devices industries.
“Adding these premier hires aligns perfectly with our firmwide strategy
of capitalizing on the impact of rapid technological change and
innovation across our key client industries,” said Mitchell
Bloom, Chair of Goodwin’s Life Sciences practice. “Malcolm, David,
Tim and Adrian bolster our well-established team in London, solidifying
Goodwin’s position as the leading firm in the UK and European life
sciences and technology markets. We are thrilled to welcome them to the
firm.”
Goodwin represents leading public and private life sciences companies
across their entire life cycles – including financings, capital market
transactions, mergers and acquisitions, collaborations and licensing,
intellectual property and regulatory matters. The firm has been named
life sciences “Practice Group of the Year” by Law360,
“Biotech Firm of the Year” by U.S. News and World Report – Best
Lawyers, and “IP Law Firm of the Year” by LMG Life Sciences.
In 2018, Goodwin advised issuers on more than a dozen biotechnology and
pharmaceutical industry IPOs worth in aggregate nearly $2 billion –
making Goodwin the number one advisor in this sector by offering value.
This work included representation of Moderna Therapeutics in the largest
biotechnology IPO in history.
Goodwin’s technology practice supports clients at all stages of the
corporate life cycle. It is consistently recognized among the very best
in the industry, including by Mergermarket, Bloomberg, PitchBook and Thomson
Reuters. Among other notable matters, the team recently advised
Carbon Black on its IPO, and advised Qualtrics International on its
acquisition by SAP SE, for which it was named “Dealmaker of the Year” by The
American Lawyer.
Over the past five years, Goodwin’s European offices have grown from
just 20 to more than 160 lawyers, including 15 dedicated to the
technology and life sciences industry verticals. The firm’s Europe-based
lawyers are widely recognized across both transactional and fund
formation practices in private equity, real estate, life sciences and
technology industries. The London office is home to nearly 100 lawyers.
About Goodwin
At Goodwin, we partner with our clients to practice law with integrity,
ingenuity, agility and ambition. Our 1,000-plus lawyers across the
United States, Europe and Asia excel at complex transactions,
high-stakes litigation and world-class advisory services in the
technology, life sciences, real estate, private equity, and financial
industries. Our unique combination of deep experience serving both the
innovators and investors in a rapidly-changing, technology-driven
economy sets us apart. To learn more, visit us at www.goodwinlaw.com
and follow us on Twitter,
LinkedIn
and Instagram.
Contacts
Konstantin Shishkin
+1.212.459.7176
[email protected]
